HRCM
AXSM icon

Hood River Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Hood River Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.6M Buy
402,678
+31,175
+8% +$6.76M 0.71% 44
2026
Q1 		$62.8M Buy
371,503
+5,327
+1% +$920K 0.63% 53
2025
Q4 		$66.9M Buy
366,176
+6,219
+2% +$868K 0.73% 53
2025
Q3 		$43.7M Sell
359,957
-11,147
-3% -$1.26M 0.52% 67
2025
Q2 		$38.7M Buy
+371,104
New +$39.3M 0.54% 65
2025
Q1 		– Sell
-644,785
Closed -$54.6M – 147
2024
Q4 		$54.6M Buy
644,785
+19,701
+3% +$1.81M 0.81% 45
2024
Q3 		$56.2M Buy
625,084
+76,018
+14% +$6.64M 0.91% 42
2024
Q2 		$44.2M Buy
549,066
+28,316
+5% +$2.1M 0.92% 38
2024
Q1 		$41.6M Buy
520,750
+127,997
+33% +$10.7M 0.93% 39
2023
Q4 		$31.3M Buy
392,753
+9,477
+2% +$634K 0.86% 46
2023
Q3 		$26.8M Sell
383,276
-1,085
-0.3% -$81.1K 0.86% 51
2023
Q2 		$27.6M Buy
384,361
+3,539
+0.9% +$261K 0.82% 55
2023
Q1 		$23.5M Sell
380,822
-79,473
-17% -$5.22M 0.76% 51
2022
Q4 		$35.5M Buy
+460,295
New +$27.5M 1.29% 29

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Hood River Capital Management's AXSM Position: Q2 2026 in Review

Hood River Capital Management increased its Axsome Therapeutics (AXSM) stake by 8.4% in Q2 2026, buying an estimated $6.76M and bringing the position to 402,678 shares worth $98.6M. The position accounts for 0.71% of the portfolio, ranked #44.

Hood River Capital Management first reported a position in AXSM in Q4 2022 and has held it in 14 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Hood River Capital Management held 402,678 shares of Axsome Therapeutics worth $98.6M as of Q2 2026.
  • Hood River Capital Management bought 31,175 Axsome Therapeutics shares in Q2 2026, an estimated $6.76M.
  • Axsome Therapeutics made up 0.71% of Hood River Capital Management's portfolio in Q2 2026, its #44 holding.
  • Hood River Capital Management first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Hood River Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.